Grifols, S.A. (VIE:GRF)

Market Cap	6.75B +24.4%
Revenue (ttm)	7.52B +7.3%
Net Income	372.72M +130.8%
EPS	0.55
Shares Out	n/a
PE Ratio	18.10
Forward PE	11.08
Dividend	0.12 (1.11%)
Ex-Dividend Date	Aug 11, 2025

Volume	n/a
Average Volume	n/a
Open	11.00
Previous Close	10.99
Day's Range	10.87 - 11.00
52-Week Range	7.41 - 13.60
Beta	n/a
RSI	49.20
Earnings Date	Feb 26, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,800
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.